Celgene pays $1.1bn up front to buy Impact; $5.9bn in earn-outs possible
Celgene Corp. is paying $1.1bn up front, plus massive potential earn-outs, to acquire privately held cancer drug developer Impact Biomedicines.
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.